Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 6/20 | 0.71 |
| ▸ | HTR6 | P50406 | 5/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | AXL | P30530 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.56 |
| ▸ | NCF1 | P14598 | 8/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | HTR5A | P47898 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.51 |
| ▸ | HTR3B | O95264 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | HTR1D | P28221 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30058924 | 0.83 | ADRB2 (1.00) | ADRB2HTR6HTR2CADRA2AAXL | |
| SCHEMBL2711296 | 0.83 | ADRB2 (1.00) | ADRB2HTR6HTR2CADRA2AAXL | |
| SCHEMBL27656377 | 0.81 | NCF1 (0.55) | ADRB2HTR6HTR2CNCF1CYP1A2 | |
| SCHEMBL2724231 | 0.79 | ADRB2 (0.90) | ADRB2HTR6HTR2CADRA2AAXL | |
| SCHEMBL428165 | 0.78 | NCF1 (0.69) | ADRB2HTR6HTR2CHTR2BNCF1 | |
| SCHEMBL430602 | 0.78 | NCF1 (0.51) | ADRB2HTR6HTR2CNCF1CYP1A2 | |
| SCHEMBL429723 | 0.78 | NCF1 (0.51) | ADRB2HTR6HTR2CNCF1CYP1A2 | |
| SCHEMBL13853243 | 0.77 | ADRB1 (0.58) | ADRB2HTR6HTR2CADRA2AAXL | |
| SCHEMBL4171704 | 0.76 | HTR6 (0.56) | ADRB2HTR6HTR2BNCF1CYP1A2 | |
| SCHEMBL430944 | 0.75 | NCF1 (0.51) | ADRB2HTR6HTR2CNCF1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| CN-101048414-B | Fused tricyclic derivatives for the treatment of psychotic disorders | GLAXO GROUP LTD | 2011-09-07 | — | — | CN | disclosed |
| CN-101048414-A | Fused tricyclic derivatives for the treatment of psychotic disorders | GLAXO GROUP LTD (GB) | 2007-10-03 | — | — | CN | disclosed |
| EP-1786822-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024517-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GABBR1, GABRQ, GABRE | ADRB2 252/4885HTR6 213/4885HTR2C 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.